Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital
Welcome,         Profile    Billing    Logout  
 3 Trials 
20 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Faggen, Meredith
postMONARCH, NCT05169567 / 2021-002301-10: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

Active, not recruiting
3
368
Europe, US, RoW
Abemaciclib, Fulvestrant, Placebo
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasm, Neoplasm Metastasis
02/24
02/26
CompassHER2 RD, NCT04457596: T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
JANUS, NCT05610163: Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation

Recruiting
2
312
US
Capecitabine, 5-fluorouracil, Leucovorin calcium, Irinotecan, Oxaliplatin, Long Course Chemoradiotherapy, Computed Tomography, Magnetic Resonance Imaging, Sigmoidoscopy, biopsy
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Locally Advanced Rectal Carcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
09/25
09/32
NCT06366347: ALPINE: Maintenance Letrozole/Abemaciclib Vs Pembrolizumab

Recruiting
2
76
US
Abemaciclib, Verzenio, LY2835219, C27H32F2N8, Letrozole, Femara, C17H11N5, Pembrolizumab, Keytruda, MK-3475, Humanized X PD-1-mAB (monoclonal antibody) (H409A11) IgG4 (immunoglobulin G4), C6504H10004N1716O2036S46
Dana-Farber Cancer Institute, Eli Lilly and Company
Endometrial Cancer, Recurrent Endometrial Cancer, TP53
09/27
03/29
ATEMPT 2.0, NCT04893109: Adjuvant T-DM1 Vs TH

Recruiting
2
500
US
trastuzumab-emtansine, T-DM1, Kadcyla, Trastuzumab SC, Herceptin Hylecta, Paclitaxel, Taxol, Onxal
Dana-Farber Cancer Institute, Genentech, Inc.
Breast Cancer, HER2-positive Breast Cancer
05/25
05/28
TRADE, NCT06001762: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

Active, not recruiting
2
90
US
Abemaciclib, Tamoxifen, Anastrozole, Letrozole, Exemestane, LHRH Agonist
Dana-Farber Cancer Institute, Eli Lilly and Company
Breast Cancer, Early-stage Breast Cancer, High Risk Breast Carcinoma
06/25
01/27
ADEPT, NCT04569747: A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

Recruiting
2
375
US
Pertuzumab+TRASTUZUMAB, PHESGO, ADJUVANT ENDOCRINE THERAPY, Letrozole, Anastrozole, Exemestane, Tamoxifen, Leuprolide, or other LHRH agonist (per investigator discretion)
Dana-Farber Cancer Institute, Genentech, Inc.
HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer, Node Negative Breast Cancer, Micrometastasis Breast Cancer, Hormone Receptor Positive Breast Cancer
09/26
09/30
NCT04266249: CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Recruiting
2
2156
US
Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Lumpectomy, Lumpectomy of Breast, Partial Mastectomy, Mastectomy, Mammectomy, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, protein-bound paclitaxel, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pertuzumab, 2C4, 2C4 Antibody, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, rhuMAb2C4, RO4368451, Radiation Therapy, Cancer Radiotherapy, Irradiate, irradiated, irradiation, RADIATION, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Trastuzumab, ABP 980, ALT02, Anti-c-ERB-2, Anti-c-erbB2 Monoclonal Antibody, Anti-ERB-2, Anti-erbB-2, Anti-erbB2 Monoclonal Antibody, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-p185-HER2, c-erb-2 Monoclonal Antibody, HER2 Monoclonal Antibody, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Herzuma, MoAb HER2, Monoclonal Antibody c-erb-2, Monoclonal Antibody HER2, Ogivri, Ontruzant, PF-05280014, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar SB3, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-QYYP, Trazimera, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO132365, RO5304020, T-DM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
10/26
12/38
NCT06100874: A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)

Recruiting
2
40
US
Sacituzumab Govitecan, Trodelvy, Trastuzumab, Herceptin, Trastuzumab and Hyaluronidase-oysk, Herceptin Hylecta
Adrienne G. Waks, Gilead Sciences
Her 2 Positive Breast Cancer, Breast Cancer Female, Breast Cancer Metastatic
11/26
11/27
Rana, Huma Q
ProGen, NCT03328091: Genetic Counseling Processes and Outcomes Among Males With Prostate Cancer

Completed
N/A
662
US
Traditional pre-test genetic counseling, Pre-test video education
Dana-Farber Cancer Institute, University of Texas Southwestern Medical Center, Barbara Ann Karmanos Cancer Institute
Prostate Cancer
02/20
02/20
OPT-IN, NCT04066361: OPTimizing Treatment Focused Genetic Testing IN Cancer

Completed
N/A
301
US
Chatbot, Video Education
Dana-Farber Cancer Institute
Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer
11/22
11/22
GENEBOPP, NCT04330716: Genetic Testing for Breast, Ovarian, Pancreatic, and Prostate Cancers

Completed
N/A
269
US
Standard Genetic Counseling, Educational Video
Dana-Farber Cancer Institute, Ambry Genetics
Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Metastatic Prostate Cancer
12/23
12/23
VERDI, NCT05225428: Video Education With Result Dependent dIsclosure

Recruiting
N/A
1020
US
Video Education, VERDI, Genetic Counseling
Dana-Farber Cancer Institute, National Cancer Institute (NCI), National Human Genome Research Institute (NHGRI)
Genetic Testing, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Colorectal Cancer, Renal Cancer, Melanoma, Sarcoma
09/25
09/26
NCT06654466: Closing the GAPS: Guideline Adherence, Prevention and Surveillance in Hereditary Cancer

Not yet recruiting
N/A
100
US
Nest, an electronic medical record (EMR)-integrated software platform to deliver longitudinal, genetics-based care at scale.
Nest Genomics, Dana-Farber Cancer Institute, National Human Genome Research Institute (NHGRI)
Hereditary Cancer Syndromes, Clinical Decision Support
03/27
09/27
NCT04248257: Peer Support For Young Adult Women With High Breast Cancer Risk

Recruiting
N/A
560
US
PeACE, Community peer coaching
Georgetown University
Breast Cancer Risk
12/25
12/25
Hixon, Nicole
NCT05168930: Zanubrutinib and Venetoclax in CLL (ZANU-VEN)

Recruiting
2
45
US
Venetoclax, Venclexta, Zanubrutinib, Brukinsa
Dana-Farber Cancer Institute, BeiGene
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
10/25
10/28
PREDICT, NCT03448926: The Registry:

Recruiting
N/A
3000
US
Treatment Recommendation Surveys, 7-gene biosignature
PreludeDx, University of South Florida
DCIS
12/25
12/35
Pashtan, Itai
NCT04155034: S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer

Recruiting
3
668
Canada, US, RoW
Magnetic Resonance Imaging, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Prophylactic Cranial Irradiation, PCI
SWOG Cancer Research Network, National Cancer Institute (NCI)
Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma
11/25
11/27
NCT03681535: Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma

Active, not recruiting
N/A
241
Europe, Japan, US, RoW
Radiation Therapy
Duke University
Diffuse Large B Cell Lymphoma
08/25
08/28
Kearney, Garrett
NCT03681535: Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma

Active, not recruiting
N/A
241
Europe, Japan, US, RoW
Radiation Therapy
Duke University
Diffuse Large B Cell Lymphoma
08/25
08/28

Download Options